{"transactions":[{"id":690300,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-11T20:39:54.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":22350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":22350,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":22350},"source":{"system":"sec-edgar","filing":"0001921956-26-000003","document":"form4-08112026_080848.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000192195626000003/form4-08112026_080848.xml","form_type":"4"}},{"id":731557,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Buy","published_at":"2026-06-18T22:45:07.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":22195,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 22,195 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":22195,"derivative":{"exercise_price":19.19,"expiration_date":"2036-06-17","underlying":"Class A ordinary shares, par value $0.0001 per share","underlying_shares":22195},"source":{"system":"sec-edgar","filing":"0001213900-26-070258","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390026070258/ownership.xml","form_type":"4"}},{"id":745767,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T22:26:10.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":7650,"derivative":{"exercise_price":4.3,"expiration_date":"2036-06-03","underlying":"Class A Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001921956-26-000002","document":"form4-06082026_100605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000192195626000002/form4-06082026_100605.xml","form_type":"4"}},{"id":1117230,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Buy","published_at":"2025-06-09T13:05:38.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":6682,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":6682,"derivative":{"exercise_price":48.83,"expiration_date":"2035-06-05","underlying":"Class A ordinary shares, par value $0.0001 per share","underlying_shares":6682},"source":{"system":"sec-edgar","filing":"0001213900-25-052365","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390025052365/ownership.xml","form_type":"4"}},{"id":1128879,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-30T20:54:43.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":7650,"derivative":{"exercise_price":2.44,"expiration_date":"2035-05-27","underlying":"Class A Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001415889-25-015019","document":"form4-05302025_080528.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000141588925015019/form4-05302025_080528.xml","form_type":"4"}},{"id":1276600,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-02-10T22:40:43.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":20491,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2025 annual meeting of the Issuer's stockholders or (ii) the date of the 2026 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date."}],"balance_after":20491,"derivative":{"exercise_price":22.47,"expiration_date":"2035-02-06","underlying":"Common Stock","underlying_shares":20491},"source":{"system":"sec-edgar","filing":"0001415889-25-003524","document":"form4-02102025_100239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588925003524/form4-02102025_100239.xml","form_type":"4"}},{"id":1389042,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-08T23:28:32.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":15300,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001415889-24-024920","document":"form4-10082024_111029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000141588924024920/form4-10082024_111029.xml","form_type":"4"}},{"id":1485993,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Buy","published_at":"2024-06-07T21:00:33.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":7688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 6, 2025, (ii) the date of the Issuer's next annual general meeting of shareholders and (iii) the date of a Change in Control (as defined in the MoonLake Immunotherapeutics 2022 Equity Incentive Plan) of the Issuer, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":7688,"derivative":{"exercise_price":42.44,"expiration_date":"2034-06-06","underlying":"Class A ordinary shares, par value $0.0001 per share","underlying_shares":7688},"source":{"system":"sec-edgar","filing":"0001213900-24-050833","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390024050833/ownership.xml","form_type":"4"}},{"id":1633768,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-21T00:35:11.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":23364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant."}],"balance_after":23364,"derivative":{"exercise_price":14.85,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":23364},"source":{"system":"sec-edgar","filing":"0001415889-24-004493","document":"form4a-02212024_120239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924004493/form4a-02212024_120239.xml","form_type":"4/A","original_submission_date":"2024-02-15"}},{"id":1640969,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-16T02:04:08.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":16835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date."}],"balance_after":16835,"derivative":{"exercise_price":14.85,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":16835},"source":{"system":"sec-edgar","filing":"0001415889-24-004028","document":"form4-02162024_020201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924004028/form4-02162024_020201.xml","form_type":"4"}},{"id":1858184,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Buy","published_at":"2023-06-12T20:47:00.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":11297,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 11,297 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 8, 2024 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":11297,"derivative":{"exercise_price":29.18,"expiration_date":"2033-06-08","underlying":"Class A ordinary shares, par value $0.0001 per share","underlying_shares":11297},"source":{"system":"sec-edgar","filing":"0001213900-23-048193","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390023048193/ownership.xml","form_type":"4"}},{"id":1923780,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-07T00:20:14.000Z","date":"2023-02-23","kind":"grant","planned":false,"acquired":true,"shares":27567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":27567,"derivative":{"exercise_price":25.28,"expiration_date":"2033-02-23","underlying":"Common Stock","underlying_shares":27567},"source":{"system":"sec-edgar","filing":"0001209191-23-023668","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123023668/doc4.xml","form_type":"4"}},{"id":2280455,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Buy","published_at":"2022-05-05T21:45:28.000Z","date":"2022-04-06","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Dr. Phillips was granted 45,000 options on April 6, 2022 pursuant to the MoonLake Immunotherapeutics 2022 Equity Incentive Plan (the \"Plan\"), vesting one-third on each of April 6, 2023, April 6, 2024 and April 6, 2025, in each case, subject to the terms of the Plan. Each option represents the right to acquire one Class A ordinary share, par value $0.0001 per share, of the Issuer."}],"balance_after":45000,"derivative":{"exercise_price":12.25,"expiration_date":"2032-04-06","underlying":"Class A ordinary shares, par value $0.0001 per share","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001213900-22-024301","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390022024301/ownership.xml","form_type":"4"}}]}